FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington.	D.C. 20	0549

washington, D.C. 20549	

washington, D.C. 20049	OMB APPROVAL		
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287	
on the control of the	Estimated average burde	n	

Filed nursuant to Section 16(a) of the Securities Eychange Act of 1934

obligations may Instruction 1(b).	continue. See		Filed p	ed pursuant to Section 16(a) of the Securities Exchange Act of 1934									per response:	0.5
					tion 30(h) of the Inv									
1. Name and Addre <u>ARONIN JE</u>			2. Issuer Name and Ticker or Trading Symbol Harmony Biosciences Holdings, Inc. [HRMY							ationship of Rep (all applicable) Director	eporting Person(s) to Issuer e) 10% Owner			
(Last)	(First)	(Middle)	[1								Officer (give below)	title	Other below)	(specify)
630 W. GERMA	ANTOWN PIKE		3. Date of Earliest Transaction (Month/Day/Year) 03/24/2022											
(Street)			<u> </u>											
PLYMOUTH MEETING	PA	19462	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applical X Form filed by One Reporting Person Form filed by More than One Reporting			n ´
(City)	(State)	(Zip)									Form filed by	, iviore	тап опе керо	rung Ferson
		Table I - No	n-Derivati	ive S	ecurities Acqu	uired,	Disp	osed of, o	r Bene	ficially (Owned			
Dat			2. Transacti Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned Followi		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
					Code	v	Amount	(A) or (D)	Price	rice Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
		Table II -	Derivativ	re Sec	curities Acqui	red, D	ispo	sed of, or	Benefi	cially O	vned			

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Deri Seci Acq or D	umber of vative urities uired (A) isposed of [Instr. 3, 45]	Expiration Date (Month/Day/Year)		d 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported	Form: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option	\$50.19	03/24/2022		A			1,180,599	(1)	03/24/2032	Common Stock	1,180,599	\$0	1,180,599	D	

Explanation of Responses:

1. The stock option shall vest in sixteen equal quarterly installments beginning on June 24, 2022.

/s/ Christian Ulrich, Attorney-in-03/28/2022

fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.